We provide you with 20 years of free, institutional-grade data for LABP stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of LABP. Explore the full financial landscape of LABP stock.
| Reported Date | CIK | Ticker | Type |
|---|
Landos Biopharma, Inc(NASDAQ:LABP) 
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative col...
Website: http://landosbiopharma.com
Founded: 2017
CEO: Josep Bassaganya-Riera
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about LABP stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.